Sees FY26 Revenue of $300M to $320M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy CRNC?
Sees FY26 revenue $300M-$320M, consensus $314.78M.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRNC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRNC
Wall Street analysts forecast CRNC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRNC is 10.50 USD with a low forecast of 10.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 7.650
Low
10.00
Averages
10.50
High
11.00
Current: 7.650
Low
10.00
Averages
10.50
High
11.00
About CRNC
Cerence Inc. is a provider of artificial intelligence (AI)-powered assistants for connected and autonomous vehicles. The Company builds AI-powered virtual assistants for the mobility/transportation market. Its software platform is used to build virtual assistants that can communicate, find information and take action across an expanding variety of categories. Its software platform has a hybrid architecture combining edge software components with cloud-connected components. Its Edge software components are installed on a vehicle’s head unit and can operate without access to external networks and information. Its Cloud-connected components comprise certain speech and natural language understanding-related technologies, AI-enabled personalization and context-based response frameworks, and a content integration platform. Virtual assistants built with its software platform address user requests across various categories, such as navigation, control, media, communication, and more.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Decline Midway, Dow Jones Falls Over 400 Points
- U.S. Stock Weakness: Midway through trading on Thursday, U.S. stocks declined significantly, with the Dow Jones dropping over 400 points, a 0.86% decrease to 49,073.13, indicating investor concerns about the economic outlook.
- Sector Performance Divergence: While real estate shares gained slightly by 0.1%, materials stocks fell by 2.2%, reflecting varying investor confidence across sectors, which could influence future investment strategies.
- Bristol Myers Earnings Beat: Bristol Myers Squibb reported fourth-quarter 2025 revenues of $12.50 billion, surpassing the consensus estimate of $12.281 billion with a 1% year-over-year increase, demonstrating resilience in a competitive pharmaceutical market.
- Weak Employment Data: U.S. job openings fell by 386,000 to 6.542 million in December, below the market estimate of 7.2 million, while initial jobless claims rose by 22,000 to 231,000, indicating challenges in the economic recovery.
See More
U.S. Stocks Decline in Morning Trading
- Market Performance: U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 200 points and the S&P 500 down 0.74% to 6,831.80, indicating weakened market sentiment and heightened investor concerns about future economic prospects.
- Sector Dynamics: Consumer staples stocks gained 0.3%, while consumer discretionary stocks fell by 2.2%, reflecting a divergence in market confidence across different consumer sectors, which could impact short-term performance of related companies.
- Economic Data: U.S. job openings declined by 386,000 to 6.542 million in December, significantly below market estimates of 7.2 million, indicating a tightening labor market that may affect future economic growth expectations.
- Initial Jobless Claims: Initial jobless claims rose by 22,000 to 231,000, exceeding market expectations of 212,000, suggesting potential pressures on the labor market that could further impact consumer confidence and spending.
See More
Align Technology Reports Strong Q4 Earnings Beat
- Earnings Beat: Align Technology reported Q4 earnings of $3.29 per share, surpassing analyst expectations of $2.97, indicating a significant improvement in profitability and boosting market confidence in future growth.
- Sales Growth: The company achieved quarterly sales of $1.047 billion, exceeding the consensus estimate of $1.033 billion, demonstrating robust performance amid strong market demand.
- Stock Surge: Align's shares jumped 10.4% in pre-market trading to $178.13, reflecting a positive investor reaction to the financial results, which may attract more investor interest.
- Increased Market Confidence: This earnings beat not only enhances Align's market image but also potentially supports its future investment and expansion plans, further solidifying its leadership position in the industry.
See More
Cerence Inc. Reports Strong Q1 2026 Earnings with Record Cash Flow
- Strong Financial Performance: Cerence reported Q1 2026 revenue of $115.1 million and adjusted EBITDA of $44.6 million, both exceeding guidance, alongside a record quarterly free cash flow of $35.6 million, indicating robust performance driven by technology and market demand.
- Technological Innovation Progress: The debut of new AI agents integrated into the xUI platform, showcased live at CES, particularly the Mobile Work AI Agent developed in partnership with Microsoft, received positive feedback from OEMs, driving active commercial negotiations and enhancing Cerence's competitiveness in the smart automotive sector.
- Key Customer Collaborations: Cerence announced partnerships with five significant clients, including JLR, Volkswagen, and Geely for xUI programs, demonstrating success against major tech competition and further solidifying its market position.
- Optimistic Future Outlook: Management reaffirmed full-year fiscal 2026 revenue guidance between $300 million and $320 million, projecting Q2 revenue between $58 million and $62 million, reflecting confidence in future growth and sustained market demand.
See More
Cerence (CRNC) Q1 2026 Earnings Call Transcript
See More
Cerence (CRNC) Q1 Earnings Preview and Growth Outlook
- Earnings Announcement: Cerence is set to announce its Q1 earnings on February 4th after market close, with a consensus EPS estimate of $0.31, reflecting a staggering year-over-year growth of 1133.3%, indicating strong profitability and market confidence.
- Strong Revenue Expectations: The anticipated revenue for Q1 is $114.51 million, representing a 125.0% year-over-year increase, showcasing Cerence's sustained growth in the automotive sector and robust market demand.
- Record of Beating Estimates: Over the past two years, Cerence has beaten EPS estimates 88% of the time and revenue estimates 100% of the time, demonstrating the company's exceptional capabilities in market analysis and execution.
- Positive Estimate Revisions: In the last three months, EPS estimates have seen 2 upward revisions and 1 downward revision, while revenue estimates have experienced 4 upward revisions with none downward, reflecting analysts' optimistic outlook on Cerence's future performance.
See More
U.S. Stocks Decline Midway, Dow Jones Falls Over 400 Points
- U.S. Stock Weakness: Midway through trading on Thursday, U.S. stocks declined significantly, with the Dow Jones dropping over 400 points, a 0.86% decrease to 49,073.13, indicating investor concerns about the economic outlook.
- Sector Performance Divergence: While real estate shares gained slightly by 0.1%, materials stocks fell by 2.2%, reflecting varying investor confidence across sectors, which could influence future investment strategies.
- Bristol Myers Earnings Beat: Bristol Myers Squibb reported fourth-quarter 2025 revenues of $12.50 billion, surpassing the consensus estimate of $12.281 billion with a 1% year-over-year increase, demonstrating resilience in a competitive pharmaceutical market.
- Weak Employment Data: U.S. job openings fell by 386,000 to 6.542 million in December, below the market estimate of 7.2 million, while initial jobless claims rose by 22,000 to 231,000, indicating challenges in the economic recovery.
See More
U.S. Stocks Decline in Morning Trading
- Market Performance: U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 200 points and the S&P 500 down 0.74% to 6,831.80, indicating weakened market sentiment and heightened investor concerns about future economic prospects.
- Sector Dynamics: Consumer staples stocks gained 0.3%, while consumer discretionary stocks fell by 2.2%, reflecting a divergence in market confidence across different consumer sectors, which could impact short-term performance of related companies.
- Economic Data: U.S. job openings declined by 386,000 to 6.542 million in December, significantly below market estimates of 7.2 million, indicating a tightening labor market that may affect future economic growth expectations.
- Initial Jobless Claims: Initial jobless claims rose by 22,000 to 231,000, exceeding market expectations of 212,000, suggesting potential pressures on the labor market that could further impact consumer confidence and spending.
See More
Align Technology Reports Strong Q4 Earnings Beat
- Earnings Beat: Align Technology reported Q4 earnings of $3.29 per share, surpassing analyst expectations of $2.97, indicating a significant improvement in profitability and boosting market confidence in future growth.
- Sales Growth: The company achieved quarterly sales of $1.047 billion, exceeding the consensus estimate of $1.033 billion, demonstrating robust performance amid strong market demand.
- Stock Surge: Align's shares jumped 10.4% in pre-market trading to $178.13, reflecting a positive investor reaction to the financial results, which may attract more investor interest.
- Increased Market Confidence: This earnings beat not only enhances Align's market image but also potentially supports its future investment and expansion plans, further solidifying its leadership position in the industry.
See More
Cerence Inc. Reports Strong Q1 2026 Earnings with Record Cash Flow
- Strong Financial Performance: Cerence reported Q1 2026 revenue of $115.1 million and adjusted EBITDA of $44.6 million, both exceeding guidance, alongside a record quarterly free cash flow of $35.6 million, indicating robust performance driven by technology and market demand.
- Technological Innovation Progress: The debut of new AI agents integrated into the xUI platform, showcased live at CES, particularly the Mobile Work AI Agent developed in partnership with Microsoft, received positive feedback from OEMs, driving active commercial negotiations and enhancing Cerence's competitiveness in the smart automotive sector.
- Key Customer Collaborations: Cerence announced partnerships with five significant clients, including JLR, Volkswagen, and Geely for xUI programs, demonstrating success against major tech competition and further solidifying its market position.
- Optimistic Future Outlook: Management reaffirmed full-year fiscal 2026 revenue guidance between $300 million and $320 million, projecting Q2 revenue between $58 million and $62 million, reflecting confidence in future growth and sustained market demand.
See More
Cerence (CRNC) Q1 2026 Earnings Call Transcript
See More
Cerence (CRNC) Q1 Earnings Preview and Growth Outlook
- Earnings Announcement: Cerence is set to announce its Q1 earnings on February 4th after market close, with a consensus EPS estimate of $0.31, reflecting a staggering year-over-year growth of 1133.3%, indicating strong profitability and market confidence.
- Strong Revenue Expectations: The anticipated revenue for Q1 is $114.51 million, representing a 125.0% year-over-year increase, showcasing Cerence's sustained growth in the automotive sector and robust market demand.
- Record of Beating Estimates: Over the past two years, Cerence has beaten EPS estimates 88% of the time and revenue estimates 100% of the time, demonstrating the company's exceptional capabilities in market analysis and execution.
- Positive Estimate Revisions: In the last three months, EPS estimates have seen 2 upward revisions and 1 downward revision, while revenue estimates have experienced 4 upward revisions with none downward, reflecting analysts' optimistic outlook on Cerence's future performance.
See More
